A Phase I, Open-Label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed Against CD47, in Subjects With Advanced Solid and Hematologic Cancers

Trial Profile

A Phase I, Open-Label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed Against CD47, in Subjects With Advanced Solid and Hematologic Cancers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 May 2017

At a glance

  • Drugs CC 90002 (Primary)
  • Indications Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 09 May 2017 Planned number of patients changed from 100 to 65.
    • 16 Aug 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Jan 2018.
    • 15 Sep 2015 Planned End Date changed from 1 Dec 2017 to 1 Jan 2018 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top